Advertisement

Targeted Therapy for Colorectal Cancer

Published:March 09, 2022DOI:https://doi.org/10.1016/j.soc.2021.11.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021 May; 71: 209-249
      1. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet Gastroenterol Hepatol. 2019; 4: 913-933
        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • et al.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; 68: 394-424
        • Dekker E.
        • Tanis P.J.
        • Vleugels J.L.A.
        • et al.
        Colorectal cancer.
        Lancet. 2019; 394: 1467-1480
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J Clin. 2020; 70: 7-30
        • Hewett D.G.
        • Rex D.K.
        The big picture: does colonoscopy work?.
        Gastrointest Endosc Clin North Am. 2015; 25: 403-413
        • Gupta S.
        • Lieberman D.
        • Anderson J.C.
        • et al.
        Spotlight: US multi-society task force on colorectal cancer recommendations for follow-up after colonoscopy and polypectomy.
        Gastroenterology. 2020; 158: 1154
        • Rex D.K.
        • Boland C.R.
        • Dominitz J.A.
        • et al.
        Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer.
        Gastroenterology. 2017; 153: 307-323
        • Kahi C.J.
        • Boland C.R.
        • Dominitz J.A.
        • et al.
        Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer.
        Gastroenterology. 2016; 150: 758-768.e11
        • Kahi C.J.
        Reviewing the evidence that polypectomy prevents cancer.
        Gastrointest Endosc Clin N Am. 2019; 29: 577-585
        • Salerno G.
        • Daniels I.
        • Heald R.J.
        • et al.
        Management and imaging of low rectal carcinoma.
        Surg Oncol. 2004; 13: 55-61
        • Bhoday J.
        • Balyasnikova S.
        • Wale A.
        • et al.
        How should imaging direct/orient management of rectal cancer?.
        Clin Colon Rectal Surg. 2017; 30: 297-312
      2. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.
        BMJ. 2006; 333: 779
        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • Bosset J.F.
        • Collette L.
        • Calais G.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Kong J.C.
        • Soucisse M.
        • Michael M.
        • et al.
        Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes.
        Ann Surg Oncol. 2021 Nov; 28: 7476-7486
        • de Lacy F.B.
        • Chadi S.A.
        • Berho M.
        • et al.
        The future of rectal cancer surgery: a narrative review of an international symposium.
        Surg Innov. 2018; 25: 525-535
        • Heald R.J.
        • Husband E.M.
        • Ryall R.D.
        The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?.
        Br J Surg. 1982; 69: 613-616
        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • You Y.N.
        • Dozois E.J.
        • Boardman L.A.
        • et al.
        Young-onset rectal cancer: presentation, pattern of care and long-term oncologic outcomes compared to a matched older-onset cohort.
        Ann Surg Oncol. 2011; 18: 2469-2476
        • Kopetz S.
        • Chang G.J.
        • Overman M.J.
        • et al.
        Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
        J Clin Oncol. 2009; 27: 3677-3683
        • Johnson B.
        • Jin Z.
        • Haddock M.G.
        • et al.
        A curative-intent trimodality approach for isolated abdominal nodal metastases in metastatic colorectal cancer: update of a single-institutional experience.
        Oncologist. 2018; 23: 679-685
        • Ali S.M.
        • Pawlik T.M.
        • Rodriguez-Bigas M.A.
        • et al.
        Timing of surgical resection for curative colorectal cancer with liver metastasis.
        Ann Surg Oncol. 2018; 25: 32-37
        • Jin Z.
        • Sanhueza C.T.
        • Johnson B.
        • et al.
        Outcome of mismatch repair-deficient metastatic colorectal cancer: the mayo clinic experience.
        Oncologist. 2018; 23: 1083-1091
        • Grothey A.
        • Fakih M.
        • Tabernero J.
        Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
        Ann Oncol. 2021 Aug; 32: 959-967
        • Muratore A.
        • Zorzi D.
        • Bouzari H.
        • et al.
        Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?.
        Ann Surg Oncol. 2007; 14: 766-770
      3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. meta-analysis group in cancer.
        J Clin Oncol. 1998; 16: 301-308
        • Colucci G.
        • Gebbia V.
        • Paoletti G.
        • et al.
        Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
        J Clin Oncol. 2005; 23: 4866-4875
        • Cassidy J.
        • Tabernero J.
        • Twelves C.
        • et al.
        XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
        J Clin Oncol. 2004; 22: 2084-2091
        • Benson A.B.
        • Venook A.P.
        • Al-Hawary M.M.
        • et al.
        Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2021; 19: 329-359
        • Requena D.O.
        • Garcia-Buitrago M.
        Molecular insights into colorectal carcinoma.
        Arch Med Res. 2020; 51: 839-844
        • Wright M.
        • Beaty J.S.
        • Ternent C.A.
        Molecular markers for colorectal cancer.
        Surg Clin North Am. 2017; 97: 683-701
        • Lai E.
        • Liscia N.
        • Donisi C.
        • et al.
        Molecular-biology-driven treatment for metastatic colorectal cancer.
        Cancers. 2020; 12: 1214
        • Scaltriti M.
        • Baselga J.
        The epidermal growth factor receptor pathway: a model for targeted therapy.
        Clin Cancer Res. 2006; 12: 5268-5272
        • Laurent-Puig P.
        • Balogoun R.
        • Cayre A.
        • et al.
        459O - ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8).
        Ann Oncol. 2016; 27: vi151
        • Kavuri S.M.
        • Jain N.
        • Galimi F.
        • et al.
        HER2 activating mutations are targets for colorectal cancer treatment.
        Cancer Discov. 2015; 5: 832-841
        • Saridaki Z.
        • Papadatos-Pastos D.
        • Tzardi M.
        • et al.
        BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome.
        Br J Cancer. 2010; 102: 1762-1768
        • Biller L.H.
        • Schrag D.
        Diagnosis and treatment of metastatic colorectal cancer: a review.
        JAMA. 2021; 325: 669-685
        • Holch J.W.
        • Ricard I.
        • Stintzing S.
        • et al.
        The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials.
        Eur J Cancer. 2017; 70: 87-98
        • Wang Z.X.
        • Wu H.X.
        • He M.M.
        • et al.
        Chemotherapy with or without anti-EGFR agents in left- and right-sided metastatic colorectal cancer: an updated meta-analysis.
        J Natl Compr Canc Netw. 2019; 17: 805-811
        • Khattak M.A.
        • Martin H.
        • Davidson A.
        • et al.
        Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
        Clin Colorectal Cancer. 2015; 14: 81-90
        • Van Cutsem E.
        • Lenz H.J.
        • Köhne C.H.
        • et al.
        Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
        J Clin Oncol. 2015; 33: 692-700
        • Douillard J.Y.
        • Siena S.
        • Cassidy J.
        • et al.
        Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
        J Clin Oncol. 2010; 28: 4697-4705
        • Heinemann V.
        • von Weikersthal L.F.
        • Decker T.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1065-1075
        • Al-Salama Z.T.
        Encorafenib: a review in metastatic colorectal cancer with a BRAF V600E mutation.
        Drugs. 2021; 81: 849-856
        • Mauri G.
        • Bonazzina E.
        • Amatu A.
        • et al.
        The evolutionary landscape of treatment for BRAF(V600E) mutant metastatic colorectal cancer.
        Cancers. 2021; 13: 137
        • Kopetz S.
        • Grothey A.
        • Yaeger R.
        • et al.
        Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.
        N Engl J Med. 2019; 381: 1632-1643
        • Meric-Bernstam F.
        • Hurwitz H.
        • Raghav K.P.S.
        • et al.
        Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
        Lancet Oncol. 2019; 20: 518-530
        • Sartore-Bianchi A.
        • Trusolino L.
        • Martino C.
        • et al.
        Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2016; 17: 738-746
        • André T.
        • Shiu K.K.
        • Kim T.W.
        • et al.
        Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.
        N Engl J Med. 2020; 383: 2207-2218
        • Allegra C.J.
        • Yothers G.
        • O'Connell M.J.
        • et al.
        Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
        J Clin Oncol. 2011; 29: 11-16
        • de Gramont A.
        • Van Cutsem E.
        • Schmoll H.J.
        • et al.
        Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
        Lancet Oncol. 2012; 13: 1225-1233
        • André T.
        • Vernerey D.
        • Im S.A.
        • et al.
        Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR group.
        Ann Oncol. 2020; 31: 246-256
        • Snoeren N.
        • van Hillegersberg R.
        • Schouten S.B.
        • et al.
        Randomized Phase III study to assess efficacy and safety of adjuvant CAPOX with or without bevacizumab in patients after resection of colorectal liver metastases: HEPATICA study.
        Neoplasia. 2017; 19: 93-99
        • Bridgewater J.A.
        • Pugh S.A.
        • Maishman T.
        • et al.
        Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 398-411